Other

Provision (benefit) for other credit losses

Year-over-year, this metric declined by 55.3%, from -$127.14M to -$197.49M. Over 3 years (FY 2021 to FY 2025), Provision (benefit) for other credit losses shows a downward trend with a -11.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026May 6, 2026

How to read this metric

An increase suggests higher expected credit risk or a deterioration in the quality of non-loan financial assets, while a decrease indicates improved credit outlook or reversals of prior provisions.

Detailed definition

This represents the periodic charge or reversal recorded in the income statement to adjust the allowance for credit loss...

Peer comparison

Standard across financial institutions under CECL or IFRS 9 accounting frameworks.

Metric ID: other_provision_for_other_credit_losses

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value-$243.76M$137.84M$266.51M$184.62M$105.71M$305.06M$308.85M$118.80M$241.23M$277.14M$583.60M$212.43M-$227.60M$164.04M-$127.14M-$203.94M$12.14M$0.00-$197.49M
QoQ Change+156.5%+93.3%-30.7%-42.7%+188.6%+1.2%-61.5%+103.0%+14.9%+110.6%-63.6%-207.1%+172.1%-177.5%-60.4%+106.0%-100.0%
YoY Change+143.4%+121.3%+15.9%-35.6%+128.2%-9.2%+391.2%-11.9%-182.1%-121.8%-196.0%+105.3%-100.0%-55.3%
Range-$243.76M$583.60M
CAGR-4.6%
Avg YoY Growth+13.8%
Median YoY Growth-10.5%
Current Streak2 quarters decline

Frequently Asked Questions

What is Royalty Pharma's provision (benefit) for other credit losses?
Royalty Pharma (RPRX) reported provision (benefit) for other credit losses of -$197.49M in Q1 2026.
How has Royalty Pharma's provision (benefit) for other credit losses changed year-over-year?
Royalty Pharma's provision (benefit) for other credit losses decreased by 55.3% year-over-year, from -$127.14M to -$197.49M.
What is the long-term trend for Royalty Pharma's provision (benefit) for other credit losses?
Over 3 years (2021 to 2025), Royalty Pharma's provision (benefit) for other credit losses has grown at a -11.0% compound annual growth rate (CAGR), from $452.84M to -$318.94M.
What does provision (benefit) for other credit losses mean?
The amount set aside or recovered to cover potential losses on non-loan financial assets.